SEC Form 4 · accession 0001708138-17-000021
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert E Landry
Officer — SVP Finance & CFO
Period of report
Aug 30, 2017
Accepted (ET)
Sep 1, 2017 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 30, 2017 | M | 2,000 | $272.70 | A | 9,099 | D | |
| Common Stock | Aug 30, 2017 | F | 1,119 | $486.91 | D | 7,980 | D | |
| Common Stock | Aug 30, 2017 | F | 454 | $486.91 | D | 7,526 | D | |
| Common Stock | Aug 31, 2017 | S | 100 | $487.88 | D | 7,426 | D | |
| Common Stock | Aug 31, 2017 | S | 100 | $489.56 | D | 7,326 | D | |
| Common Stock | Aug 31, 2017 | S | 100 | $497.42 | D | 7,226 | D | |
| Common Stock | Aug 31, 2017 | S | 127 | $497.69 | D | 7,099 | D | |
| Common Stock | holding | — | — | — | 83 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $272.70 | Aug 30, 2017 | M | 2,000 | D | — | Sep 9, 2023 | Common Stock | 2,000 | 60,000 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2The stock option award vests in four equal annual installments, commencing one year after the date of grant.